

Tizalud[®]

Tizanidine

Description

Tizanidine (Tizalud[®]) is a centrally acting skeletal muscle relaxant.

Mode of action

Tizanidine (Tizalud[®]) is an agonist at α_2 -adrenergic receptor sites and presumably reduces spasticity by increasing presynaptic inhibition of motor neurons. Tizanidine has no direct effect on skeletal muscle fibers or the neuromuscular junction, and no major effect on monosynaptic spinal reflexes. The effects of tizanidine are greatest on polysynaptic pathways. The overall effect of these actions is thought to reduce facilitation of spinal motor neurons. The imidazoline chemical structure of tizanidine is related to that of the anti-hypertensive drug clonidine and other α_2 -adrenergic agonists. Pharmacological studies in animals show similarities between the two compounds, but tizanidine was found to have one-tenth to one-fiftieth (1/50) of the potency of clonidine in lowering blood pressure.

Composition

Tizalud[®] 2: Each tablet contains Tizanidine Hydrochloride USP 2.288 mg equivalent to Tizanidine 2 mg.

Indications

It is used in the symptomatic treatment of painful muscle spasm associated with musculoskeletal conditions and as an adjunct in the management of spasticity associated with multiple sclerosis or spinal cord disorders.

Dosage & administration

The usual initial daily dose is 2 mg as a single dose. The daily dose may be increased thereafter according to response in steps of 2 mg at intervals of at least 3 to 4 days, usually up to 24 mg daily given in 3 to 4 divided doses. The maximum recommended dose is 36 mg daily.

Contraindications

Tizanidine is contraindicated to the patients who have known hypersensitivity to this drug and in case of severe hepatic impairment.

Side effects

Tizanidine may cause drowsiness, fatigue, dizziness, dry mouth, nausea, gastrointestinal disturbances, hypotension. Bradycardia, insomnia, hallucinations and altered liver enzymes, and rarely acute hepatitis have also been reported.

Use in Special Populations

Pregnancy and lactation: Tizanidine has no teratogenic effects in rats and

rabbits. As there have been no controlled studies in pregnant women, it should not be used during pregnancy unless the benefit clearly outweighs the risk. Although only small amounts of Tizanidine are excreted in animal milk, lactating women should not take Tizanidine.

Children: Experience in children is limited and the use of Tizanidine in this patient group is not recommended. **Elderly:** Renal clearance in the elderly may in some cases be significantly decreased. Caution is therefore indicated when using in elderly patients.

Precautions

Patients with impaired kidney or liver function; when patients drive a vehicle or operate machinery.

Drug Interactions

Alcohol or other CNS depressants may enhance the CNS effects of Tizanidine. There may be an additive hypotensive effect when Tizanidine is used in patients receiving antihypertensive therapy.

Overdose

A review of the safety surveillance database revealed cases of intentional and accidental tizanidine overdose. Some of the cases resulted in fatality and many of the intentional overdoses were with multiple drugs including CNS depressants. The clinical manifestations of tizanidine overdose were consistent with its known pharmacology. In the majority of cases a decrease in sensorium was observed including lethargy, somnolence, confusion and coma. Depressed cardiac function are also observed including most often bradycardia and hypotension. Respiratory depression is another common feature of tizanidine overdose. Should overdose occur, basic steps to ensure the adequacy of an airway and the monitoring of cardiovascular and respiratory systems should be undertaken. In general, symptoms resolve within one to three days following discontinuation of tizanidine and administration of appropriate therapy. Due to the similar mechanism of action, symptoms and management of tizanidine overdose are similar to those following clonidine overdose. For the most recent information concerning the management of overdose, contact a poison control center.

Storage: Store in a cool and dry place, protected from light.

Packaging

Tizalud[®] 2: Each carton contains 10X3 tablets in Alu-PVC blister pack.



Manufactured by
Opsonin Pharma Limited
Rupatali, Barishal, Bangladesh.
® Registered Trade Mark.

282-02